News

Shionogi has been Selected as one of the "Excellent Integrated Reports" by the GPIF's Domestic Equity Managers

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Shionogi Announces Corporate Reorganization and Personnel Reassignment

Dispatch employees to health centers in areas where new coronavirus infections have spread

Shionogi wins the “Environmental Report Excellence Award” for its Integrated Report/Environment Report at the “Environmental Communication Awards”

Shionogi has been recognized for “Leaderboard” in the “Supplier Engagement Leaderboard (Climate Change)”
by CDP

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Transcript for FY2020 3Q Financial Results

Financial Results for the Third Quarter of FY2020

Presentation Material for FY2020 Third Quarter Conference call

Shionogi and BioAge conclude a license agreement aimed at treating COVID-19

Shionogi Announces European Commission Approval of XOFLUZA® (Baloxavir Marboxil) for the Treatment and Post-Exposure Prophylaxis of Influenza Virus Infection

Shionogi Announces Approval of XOFLUZA® (Baloxavir Marboxil) in Taiwan for the Post-Exposure Prophylaxis of Influenza Virus Infection

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)